These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8105850)

  • 1. Chimeric antibodies for the treatment of hematologic malignancy.
    Dyer MJ
    Cancer Treat Res; 1993; 68():161-80. PubMed ID: 8105850
    [No Abstract]   [Full Text] [Related]  

  • 2. ILEX oncology acquires CD52 diagnostic rights for Campath.
    Expert Rev Mol Diagn; 2002 Nov; 2(6):525-6. PubMed ID: 12465444
    [No Abstract]   [Full Text] [Related]  

  • 3. Differential response in a patient treated with Campath-1H monoclonal antibody for refractory non-Hodgkin lymphoma.
    Lim SH; Davey G; Marcus R
    Lancet; 1993 Feb; 341(8842):432-3. PubMed ID: 8094189
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphoma.
    Dunleavy K; Wilson WH
    Leuk Lymphoma; 2010 Sep; 51(9):1583-4. PubMed ID: 20795788
    [No Abstract]   [Full Text] [Related]  

  • 5. Monoclonal antibody therapy for vasculitis.
    Lockwood CM
    Adv Exp Med Biol; 1993; 336():235-8. PubMed ID: 8296611
    [No Abstract]   [Full Text] [Related]  

  • 6. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
    Rodig SJ; Abramson JS; Pinkus GS; Treon SP; Dorfman DM; Dong HY; Shipp MA; Kutok JL
    Clin Cancer Res; 2006 Dec; 12(23):7174-9. PubMed ID: 17145843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibody therapy of lymphomas and leukemia.
    Kaminski MS; Foon KA
    Cancer Treat Res; 1988; 38():253-63. PubMed ID: 2908598
    [No Abstract]   [Full Text] [Related]  

  • 8. Antimouse CD52 monoclonal antibody inhibits established spontaneous colitis in IL-10-deficient mice.
    Zhu WM; Li Y; Yu C; Li N; Li JS
    Inflamm Bowel Dis; 2011 Jul; 17(7):E72-3. PubMed ID: 21538714
    [No Abstract]   [Full Text] [Related]  

  • 9. Expression of CD52 in peripheral T-cell lymphoma.
    Piccaluga PP; Agostinelli C; Righi S; Zinzani PL; Pileri SA
    Haematologica; 2007 Apr; 92(4):566-7. PubMed ID: 17488672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies.
    Dyer MJ
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):52-7. PubMed ID: 10561018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52).
    Osterborg A; Werner A; Halapi E; Lundin J; Harmenberg U; Wigzell H; Mellstedt H
    Eur J Haematol; 1997 Jan; 58(1):5-13. PubMed ID: 9020367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura.
    Lim SH; Hale G; Marcus RE; Waldmann H; Baglin TP
    Br J Haematol; 1993 Jul; 84(3):542-4. PubMed ID: 8217808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H.
    Ginaldi L; De Martinis M; Matutes E; Farahat N; Morilla R; Dyer MJ; Catovsky D
    Leuk Res; 1998 Feb; 22(2):185-91. PubMed ID: 9593475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of alemtuzumab and the relevance in clinical practice.
    Elter T; Molnar I; Kuhlmann J; Hallek M; Wendtner C
    Leuk Lymphoma; 2008 Dec; 49(12):2256-62. PubMed ID: 19052972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy.
    Lockwood CM; Thiru S; Isaacs JD; Hale G; Waldmann H
    Lancet; 1993 Jun; 341(8861):1620-2. PubMed ID: 8099991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CD52 antigen and development of the CAMPATH antibodies.
    Hale G
    Cytotherapy; 2001; 3(3):137-43. PubMed ID: 12171721
    [No Abstract]   [Full Text] [Related]  

  • 17. Alemtuzumab in CLL and other lymphoid neoplasms.
    Ravandi F; O'brien S
    Cancer Invest; 2006 Nov; 24(7):718-25. PubMed ID: 17118783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab.
    Osuji N; Del Giudice I; Matutes E; Morilla A; Owusu-Ankomah K; Morilla R; Dunlop A; Catovksy D
    Leuk Lymphoma; 2005 May; 46(5):723-7. PubMed ID: 16019510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia.
    Piccaluga PP; Arpinati M; Candoni A; Laterza C; Paolini S; Gazzola A; Sabattini E; Visani G; Pileri SA
    Leuk Lymphoma; 2011 Feb; 52(2):325-7. PubMed ID: 21077738
    [No Abstract]   [Full Text] [Related]  

  • 20. Monoclonal anti-CD52 antibodies: a potential mode of therapy for parvovirus B(19) hepatitis.
    Granot E; Miskin H; Aker M
    Transplant Proc; 2001 May; 33(3):2151-3. PubMed ID: 11377483
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.